Beijing Based Beigene News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Antibody cocktails cut down the risk of hospital stay during Delta, but their efficacy against Omicron is uncertain - Issue Date: Jan 24, 2022

Recent studies show the treatment may not work well against the new variant, but affluent patients continue to line up for it.

Gilead Sciences and BeiGene, which started research alliances with Shoreline Biosciences earlier this year, are among the investors in the biotech's latest financing. The preclinical-stage company technology develops cell therapies for cancer by using natural killer cells.

The Straits Times Total of 119 new therapies, heavily discounted, added for coverage by country's national insurance fund The average price cut is 10 percentage points less than last year.PHOTO: REUTERS PublishedJan 3, 2021, 5:00 am SGT https://str.sg/JDJT They can read the article in full after signing up for a free account. Share link: Or share via: Sign up or log in to read this article in full Sign up All done! This article is now fully available for you Read now Get unlimited access to all stories at $0.99/month for the first 3 months. Get unlimited access to all stories at $0.99/month f...

Drugmakers Agree to Halve Prices to Secure Access to China Bloomberg 12/28/2020 Bloomberg News © Bloomberg Capsules sit in a sample container at AstraZeneca Plc's new Biologics factory in Sodertalje, Sweden, on Thursday, April 11, 2019. AstraZeneca raised its annual sales forecast, helped by demand for the U.K. drugmaker's roster of new cancer drugs. (Bloomberg) -- Drugmakers from AstraZeneca Plc and GlaxoSmithKline Plc to BeiGene Ltd. agreed to cut prices on some of their newest drugs in China by an average of 51% in order to be covered by the country’s national insura...